[Cardiovascular irregularities in schizophrenia--more than an epiphenomenon?].
Volz
H P
HP
Ciba-Geigy GmbH Klinische Forschung, Frankfurt/Main Bundesrepublik Deutschland.
Mackert
A
A
D001143:Arousal / Q000187:drug effects / Q000502:physiology*; D001341:Autonomic Nervous System / Q000187:drug effects / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D004298:Dopamine / Q000502:physiology; D004562:Electrocardiography / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D009638:Norepinephrine / Q000502:physiology; D010464:Perazine / Q000009:adverse effects / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology*; D012565:Schizophrenic Psychology
D010464:Perazine; D004298:Dopamine; D009638:Norepinephrine
Kardiovaskuläre Regulationsstörungen bei Schizophrenen--mehr als ein Epiphänomen?